Molbio Diagnostics Aims for Growth with ₹200 Crore IPO

Molbio Diagnostics, a key player in the molecular diagnostics sector, is preparing to launch an initial public offering (IPO) that aims to secure ₹200 crore for capital expenditures. The company also plans to generate an additional ₹740 crore through an offer for sale, which will reduce the promoter group's stake from 46.6% to 43%.

Expanding Global Reach

Established in 2000, Molbio Diagnostics has developed a robust presence in over 90 countries, supported by six manufacturing facilities across India. Known for its focus on both infectious and non-communicable diseases, the company’s flagship product is the 'Truenat' platform. This portable diagnostics system is especially designed for resource-limited settings and provides accurate test results within an hour, making it a crucial tool in global health initiatives.

The company’s revenue primarily comes from its diagnostic test kits, with tuberculosis kits alone contributing to 70% of the sales. The reliance on a few major clients, who account for over half of the revenue, highlights a concentration risk but also underscores the trust in their products.

Financial Performance and Market Position

Molbio Diagnostics has shown impressive financial growth in recent years. Between FY24 and FY26, the company's revenue from operations increased by 31.5% annually, reaching ₹1,445.7 crore. During the same period, net profit rose by 40.2% to ₹164.1 crore, while EBITDA grew 33.2% to ₹328.2 crore, with an improved margin of 22.6% in FY26 compared to 22% in FY24.

The company's valuation, post-IPO, suggests a price-earnings (P/E) multiple of up to 57. While there are no directly comparable listed peers in India, similar companies in the healthcare diagnostics and medical devices sector, such as Poly Medicure and Dr. Lal PathLabs, have P/E multiples ranging from 54 to 81.

Potential for High-Risk Investors

For investors with a high-risk appetite, Molbio Diagnostics' IPO presents an opportunity to invest in a company with strong growth potential and a significant global footprint. The funds raised are expected to support further expansion and innovation in diagnostic solutions. However, the heavy reliance on a few major clients and the competitive valuation are factors that potential investors should consider.

As Molbio Diagnostics continues to advance its offerings and expand its market share, the IPO could provide the capital needed to sustain long-term growth, positioning the company as a pivotal player in the global diagnostics landscape.